Immunotherapy shrinks tumors in genetic subtype of colon cancer
Disease control
Completed
This study tested an immunotherapy drug called prolgolimab in 30 people with stage II-III colorectal cancer that has a specific genetic feature (MSI/dMMR). Participants received the drug for 6 months before surgery. The main goal was to see if the cancer completely disappeared by…
Phase: PHASE2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated May 16, 2026 23:38 UTC